Myeloid neoplasm
MONDO:0005170Proliferation of myeloid cells originating from a primitive stem cell.
Also known as: myeloid malignancy, myeloid neoplasm, myeloid tumor, myeloid tumour
4465 clinical trials for this condition and its sub-types, 48 tagged with Myeloid neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Myeloid neoplasm
-
Myeloproliferative neoplasm 166 trials · 1,632 incl. sub-types
13 sub-types
- Myeloid leukemia 30 trials · 1,334 incl. sub-types Sub-types →
- Myelodysplastic/myeloproliferative neoplasm 81 trials · 234 incl. sub-types Sub-types →
- Primary myelofibrosis 191 trials · 195 incl. sub-types Sub-types →
- Myelofibrosis 149 trials
- Erythroid neoplasm 0 trials · 95 incl. sub-types Sub-types →
- Essential thrombocythemia 67 trials
- Therapy-related myeloid neoplasm 54 trials
- Myeloproliferative neoplasm, unclassifiable 11 trials · 16 incl. sub-types Sub-types →
- Transient myeloproliferative syndrome 13 trials
- Chronic neutrophilic leukemia 10 trials
- Chronic eosinophilic leukemia 9 trials
- Myeloproliferative disease, autosomal recessive 0 trials
- Thrombocytopenia 6 0 trials
-
Plasma cell myeloma 1,108 trials · 1,131 incl. sub-types
3 sub-types
- Smoldering plasma cell myeloma 63 trials · 64 incl. sub-types Sub-types →
- Non-secretory plasma cell myeloma 1 trial
- Osteosclerotic plasma cell myeloma 0 trials
-
Mast cell neoplasm 0 trials · 34 incl. sub-types
2 sub-types
- Mastocytosis 15 trials · 34 incl. sub-types Sub-types →
- Mastocytoma 0 trials Sub-types →
-
CD4+/CD56+ hematodermic neoplasm 31 trials
Most studied deeper sub-types
-
Personalized stem cell transplant aims to beat inherited blood cancers
Disease control Not yet recruitingThis study tests whether adjusting chemotherapy doses for each patient can improve outcomes after a stem cell transplant for blood cancers caused by a RUNX1 gene mutation. Up to 98 people aged 4 to 70 with these cancers will receive a transplant from a half-matched donor. The goa…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 14:00 UTC
-
Can donor immune cells tame stem cell transplant risks?
Disease control Not yet recruitingThis trial tests whether an experimental cell therapy called agenT-797 is safe for people receiving a stem cell transplant for blood cancers like leukemia or myelodysplastic syndrome. Participants get an infusion of agenT-797 about a week after their transplant. The main goal is …
Phase 1 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New study aims to stop blood cancer relapse after transplant
Disease control Not yet recruitingThis study tests whether giving personalized maintenance therapy after a stem cell transplant can prevent cancer from coming back in people with certain blood cancers. About 450 adults with myeloid cancers who have signs of disease before transplant will be assigned to treatment …
Phase 2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug cocktail targets deadliest blood cancers
Disease control Not yet recruitingThis trial investigates whether adding selinisole to standard chemotherapy drugs (azacitidine and venetoclax) can improve outcomes for people with newly diagnosed, high-risk myeloid tumors that have a TP53 mutation. These tumors are aggressive and hard to treat. The study will me…
Sponsor: Bing Han • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New pill takes on tough blood cancers in first human trial
Disease control Not yet recruitingThis early-stage study tests a new tablet, FXS0683, in 228 adults with blood cancers like lymphoma or leukemia that returned or didn't respond to standard therapy. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will be clo…
Phase 1 • Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC